Directive 2012/26/EU
E1533650
UNEXPLORED
Directive 2012/26/EU is a European Union legislative act that strengthened pharmacovigilance rules and safety monitoring for medicinal products for human use by updating the EU’s medicines regulatory framework.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Directive 2012/26/EU canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22404545 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Directive 2012/26/EU Context triple: [Directive 2001/83/EC, amendedBy, Directive 2012/26/EU]
-
A.
Directive 2013/37/EU
Directive 2013/37/EU is a European Union law that updated and expanded the rules on the re-use of public sector information to promote transparency, innovation, and economic activity across the EU.
-
B.
Directive 2010/53/EU
Directive 2010/53/EU is a European Union law that sets common standards for the quality and safety of human organs intended for transplantation across EU member states.
-
C.
Directive 2014/65/EU
Directive 2014/65/EU is a key European Union legislative act that overhauls and strengthens the regulatory framework for investment services and financial markets, commonly known as MiFID II.
-
D.
Directive 2013/36/EU
Directive 2013/36/EU is a key European Union legislative act that sets prudential rules and supervisory standards for credit institutions and investment firms as part of the EU’s post-crisis banking regulation framework.
-
E.
Directive 2014/34/EU
Directive 2014/34/EU is a European Union law that harmonizes safety requirements for equipment and protective systems intended for use in potentially explosive atmospheres (ATEX) within the EU internal market.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Directive 2012/26/EU Target entity description: Directive 2012/26/EU is a European Union legislative act that strengthened pharmacovigilance rules and safety monitoring for medicinal products for human use by updating the EU’s medicines regulatory framework.
-
A.
Directive 2013/37/EU
Directive 2013/37/EU is a European Union law that updated and expanded the rules on the re-use of public sector information to promote transparency, innovation, and economic activity across the EU.
-
B.
Directive 2010/53/EU
Directive 2010/53/EU is a European Union law that sets common standards for the quality and safety of human organs intended for transplantation across EU member states.
-
C.
Directive 2014/65/EU
Directive 2014/65/EU is a key European Union legislative act that overhauls and strengthens the regulatory framework for investment services and financial markets, commonly known as MiFID II.
-
D.
Directive 2013/36/EU
Directive 2013/36/EU is a key European Union legislative act that sets prudential rules and supervisory standards for credit institutions and investment firms as part of the EU’s post-crisis banking regulation framework.
-
E.
Directive 2014/34/EU
Directive 2014/34/EU is a European Union law that harmonizes safety requirements for equipment and protective systems intended for use in potentially explosive atmospheres (ATEX) within the EU internal market.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.